Deferasirox Supplier in Nepal
DEFRATAJ — WHO-GMP Deferasirox dispersible tablets, supplied direct from the manufacturer to DDA-registered importers.
Supply & Market
DEFRATAJ (Deferasirox) dispersible tablets are exported to Nepal by Taj Pharma India Ltd. as a long-standing manufacturing partner for South-East Asian markets. Tablets are produced under WHO-GMP at the Sarigam plant and reach Taj Pharma India Ltd. via Singapore, Port Klang, Ho Chi Minh City and Manila ports with full Nepal-Pharmacopoeia compliance.
The Nepal market for iron-chelation therapy is driven by a high regional prevalence of thalassemia and other transfusion-dependent anaemias, where Deferasirox is the preferred once-daily oral chelator.
Our regulatory and commercial team in Mumbai partners directly with importers, hospital procurement officers and Ministry-of-Health tender desks across Nepal — from Kathmandu to regional referral centres — for streamlined supply continuity.
Supply Capability for Nepal
DEFRATAJ is supplied to Nepal across all five strengths — 100 mg, 125 mg, 250 mg, 400 mg and 500 mg dispersible tablets — in HDPE bottles (30s/60s/100s) and Alu-Alu blister packs. Minimum-order quantities start at 50,000 tablets per strength with a typical lead time of 4–6 weeks from PO confirmation.
- Strengths shipped: 100 mg, 125 mg, 250 mg, 400 mg, 500 mg dispersible tablets
- Pack sizes: bottles (30/60/100 tabs), Alu-Alu blisters (10x10), hospital institutional packs
- MOQ: 50,000 tablets per strength per shipment (mixed pallets supported)
- Lead time: 4–6 weeks ex-Mumbai (JNPT / Nhava Sheva)
- Shelf life: 24 months at 25°C / 60% RH (Zone IVb stability data on file)
- Documents per shipment: CoA, CoO, packing list, invoice, BL/AWB, free-sale certificate
- Private label / co-branding: available with own artwork and brand registration
Cold-chain is not required for dispersible tablets, but climatised containers can be arranged on request for hot-route lanes into Nepal.
Regulatory Pathway in Nepal
Deferasirox dispersible tablets are registered in Nepal with the Department of Drug Administration (DDA). Taj Pharma submits the full CTD dossier (Modules 1–5) along with our WHO-GMP certificate, CoPP, manufacturing licence, plant master file and validated stability data to DDA. Our regulatory desk handles queries, sample submissions and post-approval variations on behalf of local marketing-authorisation holders.
Local agent appointment, secondary packaging in Nepali, and pharmacovigilance reporting are all coordinated from our Mumbai head office. Documentation can be couriered or e-submitted to DDA in Kathmandu.
- CTD dossier (Modules 1–5) ready
- WHO-GMP · ISO 9001 · PIC/S-aligned plant
- CoPP & manufacturing licence on request
- Stability data (long-term & accelerated, Zone IVb)
- Country code
NP· trade currency Nepalese Rupee